PMID- 34249430
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210713
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 11
IP  - 6
DP  - 2021
TI  - Differential molecular response of larynx cancer cell lines to combined VPA/CDDP 
      treatment.
PG  - 2821-2837
AB  - Successful treatment of advanced larynx squamous cell carcinoma (LSCC) remains a 
      challenge, mainly due to limited response to chemotherapy and the phenomenon of 
      the drug resistance. Therefore, new chemotherapeutic solutions are needed. The 
      aim of this study was to explore benefit of combined cisplatin (CDDP) and 
      valproic acid (VPA) therapy in patients' derived LSCC cell lines. Cell viability 
      assay was used to establish cellular response to the drug by isobolography 
      followed by RNA sequencing (RNAseq) analysis. Danio rerio were used for in vivo 
      studies. Depending on the cell line, we found that the combinations of drugs 
      resulted in synergistic or antagonistic pharmacological interaction, which was 
      accompanied by significant changes in genes expression profiles. The presented 
      therapeutic scheme efficiently blocked tumor growth in an in vivo model, 
      corresponding to the in vitro performed studies. Interestingly the RK5 cell line, 
      upon the combined treatment acquired a molecular profile typically associated 
      with epithelial to mesenchymal transition (EMT). Hence, our studies demonstrates 
      that patient-specific personalized therapy of larynx cancer should be considered 
      and the combination of cisplatin and valproic acid should be explored as a 
      potential therapeutic strategy in the treatment of larynx cancer.
CI  - AJCR Copyright (c) 2021.
FAU - Gumbarewicz, Ewelina
AU  - Gumbarewicz E
AD  - Department of Biochemistry and Molecular Biology, Medical University of Lublin 
      Chodzki 1 St., 20-093 Lublin, Poland.
FAU - Tylzanowski, Przemko
AU  - Tylzanowski P
AD  - Department of Biochemistry and Molecular Biology, Medical University of Lublin 
      Chodzki 1 St., 20-093 Lublin, Poland.
AD  - Laboratory for Developmental and Stem Cell Biology, Department of Development and 
      Regeneration, Skeletal Biology and Engineering Research Centre, University of 
      Leuven Leuven, Belgium.
FAU - Luszczki, Jarogniew
AU  - Luszczki J
AD  - Department of Pathophysiology, Medical University Lublin, Poland.
FAU - Kalafut, Joanna
AU  - Kalafut J
AD  - Department of Biochemistry and Molecular Biology, Medical University of Lublin 
      Chodzki 1 St., 20-093 Lublin, Poland.
FAU - Czerwonka, Arkadiusz
AU  - Czerwonka A
AD  - Department of Biochemistry and Molecular Biology, Medical University of Lublin 
      Chodzki 1 St., 20-093 Lublin, Poland.
FAU - Szumilo, Justyna
AU  - Szumilo J
AD  - Department of Clinical Pathomorphology, Medical University of Lublin Lublin, 
      Poland.
FAU - Wawruszak, Anna
AU  - Wawruszak A
AD  - Department of Biochemistry and Molecular Biology, Medical University of Lublin 
      Chodzki 1 St., 20-093 Lublin, Poland.
FAU - Kupisz, Krzysztof
AU  - Kupisz K
AD  - Department of Otolaryngology and Laryngeal Oncology, Medical University of Lublin 
      Lublin, Poland.
AD  - Department of Otolaryngology, Center of Oncology of The Lublin Region Lublin, 
      Poland.
FAU - Polberg, Krzysztof
AU  - Polberg K
AD  - Department of Otolaryngology, MSWiA Hospital Lublin, Poland.
FAU - Smok-Kalwat, Jolanta
AU  - Smok-Kalwat J
AD  - Department of Clinical Oncology, Holycross Cancer Centre Kielce, Poland.
FAU - Stepulak, Andrzej
AU  - Stepulak A
AD  - Department of Biochemistry and Molecular Biology, Medical University of Lublin 
      Chodzki 1 St., 20-093 Lublin, Poland.
LA  - eng
PT  - Journal Article
DEP - 20210615
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC8263637
OTO - NOTNLM
OT  - Laryngeal cancer
OT  - cisplatin
OT  - gene expression
OT  - valproic acid
COIS- None.
EDAT- 2021/07/13 06:00
MHDA- 2021/07/13 06:01
PMCR- 2021/06/15
CRDT- 2021/07/12 05:53
PHST- 2020/04/17 00:00 [received]
PHST- 2021/05/14 00:00 [accepted]
PHST- 2021/07/12 05:53 [entrez]
PHST- 2021/07/13 06:00 [pubmed]
PHST- 2021/07/13 06:01 [medline]
PHST- 2021/06/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2021 Jun 15;11(6):2821-2837. eCollection 2021.